Skip to main content
Premium Trial:

Request an Annual Quote

NextGxDx Offering PreventionGenetics' Test Catalog

NEW YORK (GenomeWeb News) – NextGxDx will begin offering PreventionGenetics' test catalog through the NextGxDx platform under an agreement announced today.

The deal adds hundreds of new genetic tests "to the NextGxDx marketplace for easy search, comparison, and ordering," NextGxDx said. Financial and other terms of the deal were not disclosed.

"PreventionGenetics adds tremendous depth to our catalog and enhances the choice of genetic testing products available to health care providers through our platform," Judsen Schneider, NextGxDx scientific director, said in a statement. "Given their commitment to the research and development of new genetic testing products, we expect that catalog will continue to expand over time."

Nashville, Tenn.-based NextGxDx said last week it had raised $1 million in a private financing round.

The company offers an online platform that allows healthcare professionals to access listings of genetic tests from CLIA-certified laboratories, order them, and view the test results.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.